T1D Fund is a venture philanthropy fund focused on accelerating life-changing solutions for people with type 1 diabetes through catalytic commercial investments.

T1D Fund

JDRF International

The T1D Fund is a venture philanthropy fund accelerating life-changing solutions to treat, prevent, and ultimately cure T1D.  Launched in December 2016, our aim is to attract and deploy capital to advance promising disease-modifying therapies and provide cures for those living with T1D.  It’s the first scaled, mission-driven venture philanthropy fund focused on equity investments in partnership with additional sources of capital, including venture capital, corporations, and foundations.  By investing in areas strategically aligned with Breakthrough T1D (Formerly JDRF), the leading global T1D research and advocacy organization, we can exclusively focus on supporting innovative approaches and novel mechanisms with curative potential.  We are a mission-driven organization that continues to support companies that play a role in the discovery and therapeutic development of effective solutions to T1D. 

The #T1DFund team is looking forward to attending #ada2024 – we're very excited to hear about all the latest scientific advances in #t1d as well as hear from many experts in the field. Be sure to check out the #scientificsessions where some of our portfolio companies like SAB BIO will be presentation. We can't wait to see everyone there!

We're proud to support Cour Pharmaceuticals Development Co., Inc. and their groundbreaking work in treating type 1 diabetes. In a  recent Q&A with Drug Target Review, CEO John J. Puisis delves into the innovative nanoparticle platform behind their preclinical T1D program, CNP-103. This cutting-edge technology is showing promise in addressing the immune-mediated destruction of pancreatic islet cells, offering hope for halting disease progression in T1D. Exciting advancements like these exemplify the potential of our investments to transform lives.

#T1DResearch #InnovativeHealthcare #T1D

Congratulations to the SAb Biotherapeutics team for achieving FDA clearance for SAB-142's IND. We are proud to support your efforts towards the clinic which has great potential for the type one diabetes community. The program is promising as a disease modifying therapy for T1D. #t1d

The JDRF T1D Fund is seeking a Chief of Staff to join our team and work alongside our team of investment and operations professionals. This is a unique opportunity to join a leading Venture Philanthropy whose mission is to accelerate life-changing solutions to treat, prevent, and cure type 1 diabetes (T1D).

https://lnkd.in/dWXJSZ8s

Join our Managing Director Katie Ellias on May 10 at 1:45pm ET at the 2024 Convergence Forum for a panel discussion on the funding strategy of foundations. The annual gathering brings together high-level healthcare leaders to discuss and debate the most pressing topics of interest to the industry. To learn more, visit: https://lnkd.in/ejeUvSBb
 
#2024convergenceforum #employeespotlight #healthcareinnovaton

Welcome Lisa Olson as the CEO of Enthera Pharmaceuticals – we’re thrilled to have you on the team as the company announces the successful kick-off of its Ph1b trial in #ulcerativecolitis and plans to embark on future trials in #T1D to halt islet cell death and preserve beta cell mass and function.

https://lnkd.in/eitBskY6

ORG:T1DFUND

T1D Fund

name

homepage url

country

linkedin url

employee count

sector

industry

Description

invested in

Metrics